Biomedical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1-504-608-2390

Research Article - Biomedical Research (2017) Volume 28, Issue 21

Combinational effect of laparoscopic surgery and neoadjuvant chemotherapy on patients with colorectal cancer

Objective: To investigate the combinational effect of laparoscopic surgery and neoadjuvant chemotherapy on the treatment of colorectal cancer by analyzing the serum levels of Caudal type homologous transcription factor-2 (CDX-2), Proto-oncogene (C-erbB-2) and Intercellular Adhesion Molecule-1 (ICAM-1) in patients before and after treatment.

Methods: 90 cases of colorectal cancer patients cheated in our hospital from April 2011 to April 2012 were selected, randomly divided into study group and control group. Each group has 90 cases. The control group was treated with laparoscopic surgery, and the study group was treated with neoadjuvant chemotherapy combined with laparoscopic surgery. The clinical efficacy, adverse reaction and survival rate, and levels of CDX-2, C-erbB-2 and ICAM-1 before and after treatment were compared between the two groups.

Results: The total effective rate was 66.7% in the study group, which was significantly higher than that in the control group (42.2%). The levels of CDX-2, C-erbB-2 and ICAM-1 in the study group were significantly lower than those in the control group after treatment. The incidence of adverse reactions in study group was 4.4%, and the incidence of adverse reactions in control group was 20.0%. The median overall survival time in control group was 29 months (95% CI: 19.176-36.672) and the median overall survival time in study group was 40 months (95% CI: 28.205-49.617). The 3 y and 5 y survival rates of study group were significantly higher than those of control group.

Conclusion: Combination of laparoscopic surgery combined with neoadjuvant chemotherapy has a high value for clinical treatment of colorectal cancer. It can reduce serum CDX-2, C-erbB-2 and ICAM-1 levels and improve prognosis of patients, thus deserving further application and promotion.

Author(s): Yijun Li, Qingwen Xu, Yunyun Cen, Pengyuan Xu, Dali Sun, Weiming Li, Shumin Li, Ting Yang, Yanbo Sun, Yueying Lin

Abstract Full Text PDF

Get the App

best replica reviews